Clinical trials: Antipsychotic Agents
Schizophrenia
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
- Trial name
- NCT01760993
- Testing
- SPD489
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Shire
Schizophrenia and Related Disorders, Drug Administration Schedule
"Extended" (Alternate Day) Antipsychotic Dosing
The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment.
- Conditions
- Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
- Trial name
- NCT04478838
- Testing
- Risperidone, Olanzapine, paliperidone
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Obesity, Abdominal Obesity
Application of the SIMPLE Program for Weight Loss at Pathways to Housing: A Feasibility Study
The objective of this study is to assess feasibility of the application of an adapted version, with permission, of Dr. Cenk Tek's Simplified Intervention to Modify Physical activity, Lifestyle, and Eating behavior (SIMPLE…
- Trial name
- NCT03389425
- Testing
- simplified intervention to modify physical activity, lifestyle, and eating behavior
- Volunteers
- 9 people
- Sponsor
- University of Calgary
Bipolar Disorders, Manic Disorder
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers in the treatment of manic episodes associated with bipolar…
- Trial name
- NCT00253149
- Testing
- risperidone
- Volunteers
- 158 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Scizophrenia
Carbergoline for Antipsychotic Induced Hyperprolactinemia.
The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia.
- Trial name
- NCT07386080
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Zealand University Hospital
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Schizophrenia
Antipsychotic Therapy and First Episode
For schizophrenic patients who remained in remission while on maintenance medication, there may come a point in time when the relative risk for relapse become so low that discontinuation of therapy can be considered.
- Trial name
- NCT00334035
- Testing
- Quetiapine
- Where
- Hong Kong
- Volunteers
- 169 people
- Sponsor
- The University of Hong Kong
Autism, Aggression
The Family VOICE Study
Family centered mental health treatment with children values and supports the role of parents in their child's recovery. However, medications are often the primary focus in community treatment, even in preschool age youth, with…
- Conditions
- Autism, Aggression, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT01804582
- Testing
- Family Navigator consultation
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC
Antipsychotic Agents, Bipolar Disorder
Pharmacoepigenetics of Bipolar Disorder Treatment
Insulin is a hormone produced by the body to regulate blood sugar. Insulin resistance is a state when the body is not using insulin correctly, and more insulin is needed to maintain normal blood sugar.
- Trial name
- NCT02374996
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wayne State University
Bipolar Depression
What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?
PURPOSE The purpose of this study is to elucidate whether quetiapine fumurate (Seroquel) exerts its antidepressant activity in bipolar disorder through altering either serotonergic or catecholinergic activity.
- Trial name
- NCT00817323
- Testing
- Dietary amino-acid depletion
- Sponsor
- University of British Columbia
Psychotic Disorders, Schizophrenia
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
This is a prospective study using a concierge model of customized adherence enhancement and long-acting injectable antipsychotic (CAL-Concierge) in 30 individuals with schizophrenia or schizoaffective disorder at risk for…
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence
- Trial name
- CAL-C (NCT02085447)
- Testing
- CAE-L
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
International Observational Registry on Schizophrenia
- Trial name
- NCT01026285
- Testing
- Risperidone Long-Acting injectable or oral antipsychotics
- Where
- 98 sites in Czechia, France and 6 more
- Volunteers
- 1,085 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia
The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of inpatients with schizophrenia.
- Trial name
- SPIN (NCT01214135)
- Where
- 14 sites in Sweden
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Insulin Resistance, Metabolic Syndrome X
Side Effects of Antipsychotic Medications
Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to…
- Conditions
- Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders
- Trial name
- NCT00363181
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Stanford University
Schizophrenia
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be…
- Trial name
- NCT00086593
- Testing
- lamotrigine
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline
Antipsychotic Drug- Toxicity
Pattern of Acute Antipsychotic Drug- Toxicity in Children
Pattern of Acute Antipsychotic Drug- Toxicity in Children at Assiut University Children Hospital. Determine the pattern and outcome of acute antipsychotic drug- toxicity of children who are admitted to The emergency department of…
- Trial name
- NCT06125275
- Volunteers
- 50 people
- Sponsor
- Assiut University
Antipsychotics in Palliative Care
Use of Antipsychotics in Palliative Care (NEUROPAL)
There are not lots of recommendations for the use of antipsychotics in palliative care. The National Agency for Accreditation and Evaluation in Health (ANAES) and the French Society for Accompaniment and Palliative Care, in 2002…
- Trial name
- NEUROPAL (NCT03155685)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Caen